Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by palinc2000on Mar 09, 2021 11:38am
119 Views
Post# 32752696

Comparing Market caps in Nash related companies

Comparing Market caps in Nash related companiesPaul is not there yet and for good reasons,,,First of all if you compare market caps you need to compare other mertics such as cash on hand ,published clinical results  clinical results ,depth and duration of ongoing clinical trials etc etc   
One of the slided today did compare Grinspoon study results of other Nash companies,,,This is what really counts ,,,,but comparing market caps would sound like whining about the markets and analysts getting this all wrong,,,,Paul can in one on one meetings convey that THTX is not fairly valued but the solution to change that is HIS and HIS only,,,,,,,
The markets perception of THTX casts a dark cloud on the valuation,,,Paul is very aware of this fact,,,
Thats why he needs to spend more time on selling himself ,,,,,and confirm /convibce that he is the real Mckoy.....,,Valuation will follow and at some point there will be a snowball effect 

So complaining about the market not recognizing the company s  valuue is not the way to fix,, things,,,,,I think Paul is well aware of the perception and he wants to change this in a professional manner and my bet is that he will succeed
<< Previous
Bullboard Posts
Next >>